Literature DB >> 16314954

Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells.

Zhi-Min Wu1, Xian-Hou Yuan, Pu-Cha Jiang, Zhi-Qiang Li, Tao Wu.   

Abstract

To examine the role of focal adhesion kinase in human glioma cells, we studied its effects on proliferation and apoptosis using FAK antisense oligonucleotide. U251 MG cells were transfected with ODNs, sense FAK, mismatch FAK and antisense-FAK, respectively. Expression of FAK proteins were detected by Western blots and Immnofluoressence. Cell apoptosis and mitochondrial membrane potential were analyzed by flow cytometry. Caspase-3 activity was measured by spectrofluorometer. MTT assay was used to examine changes in cell proliferation. The protein expression of FAK in U251 MG cells decreased in antisense-FAK ODNs group significantly. Caspase-3 activity increased in cells treated with antisense-FAK and down-regulated when treated with caspase-3 inhibitor. The level of cell apoptosis and loss of mitochondrial membrane potential in antisense-FAK group was higher than in the mismatch sense group. Cells proliferation was inhibited by antisense-FAK, and the effects were clearly additive when antisense oligonuceotides were added to cells treated with the anticancer agents. The results suggest that antisense-FAK ODNs inhibit U251 MG cells proliferation and induce their apoptosis. It is possible that FAK via mitochondrial and caspase-3 inhibits U251 MG cells apoptosis. And antisense oligonucleotide treatment enhances U251 MG cells sensitivity to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314954     DOI: 10.1007/s11060-005-9025-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  24 in total

Review 1.  Antisense oligonucleotides as therapeutic agents.

Authors:  A Alama; F Barbieri; M Cagnoli; G Schettini
Journal:  Pharmacol Res       Date:  1997-09       Impact factor: 7.658

2.  Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.

Authors:  R Zhang; R P Iyer; D Yu; W Tan; X Zhang; Z Lu; H Zhao; S Agrawal
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

3.  Role of ceramide during cisplatin-induced apoptosis in C6 glioma cells.

Authors:  S Noda; S Yoshimura; M Sawada; T Naganawa; T Iwama; S Nakashima; N Sakai
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

4.  Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset.

Authors:  R Kronenwett; U Steidl; M Kirsch; G Sczakiel; R Haas
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

Review 5.  The focal adhesion kinase--a regulator of cell migration and invasion.

Authors:  Christof R Hauck; Datsun A Hsia; David D Schlaepfer
Journal:  IUBMB Life       Date:  2002-02       Impact factor: 3.885

6.  Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells.

Authors:  C Blanc; Q L Deveraux; S Krajewski; R U Jänicke; A G Porter; J C Reed; R Jaggi; A Marti
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

7.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma.

Authors:  A Webb; D Cunningham; F Cotter; P A Clarke; F di Stefano; P Ross; M Corbo; Z Dziewanowska
Journal:  Lancet       Date:  1997-04-19       Impact factor: 79.321

8.  Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein.

Authors:  Hiromasa Sasaki; Fumikazu Kotsuji; Benjamin K Tsang
Journal:  Gynecol Oncol       Date:  2002-05       Impact factor: 5.482

9.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

Authors:  M M Keane; S A Ettenberg; M M Nau; E K Russell; S Lipkowitz
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

10.  Primary glial tumor patients treated by combining cis-platin and etoposide.

Authors:  A Boiardi; A Silvani; I Milanesi; M Botturi; G Broggi
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

View more
  6 in total

1.  FAK is involved in invasion and metastasis of hepatocellular carcinoma.

Authors:  Jing-Song Chen; Xiao-Hui Huang; Qian Wang; Xi-Lin Chen; Xin-Hui Fu; Hao-Xiang Tan; Long-Juan Zhang; Wen Li; Jiong Bi
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

2.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer.

Authors:  Victoria Bolós; Joan Manuel Gasent; Sara López-Tarruella; Enrique Grande
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

3.  A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Authors:  Suzanne F Jones; Lillian L Siu; Johanna C Bendell; James M Cleary; Albiruni R A Razak; Jeffrey R Infante; Shuchi S Pandya; Philippe L Bedard; Kristen J Pierce; Brett Houk; W Gregory Roberts; S Martin Shreeve; Geoffrey I Shapiro
Journal:  Invest New Drugs       Date:  2015-09-04       Impact factor: 3.850

4.  The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer.

Authors:  Stefanie Tiede; Nathalie Meyer-Schaller; Ravi Kiran Reddy Kalathur; Robert Ivanek; Ernesta Fagiani; Philip Schmassmann; Patrick Stillhard; Simon Häfliger; Norbert Kraut; Norbert Schweifer; Irene C Waizenegger; Ruben Bill; Gerhard Christofori
Journal:  Oncogenesis       Date:  2018-09-20       Impact factor: 7.485

5.  Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.

Authors:  Cheng-Shi Xu; Ze-Fen Wang; Li-Ming Dai; Sheng-Hua Chu; Ling-Ling Gong; Ming-Huan Yang; Zhi-Qiang Li
Journal:  J Transl Med       Date:  2014-05-27       Impact factor: 5.531

6.  Novel anticancer agent, SQAP, binds to focal adhesion kinase and modulates its activity.

Authors:  Jesus Izaguirre-Carbonell; Hirofumi Kawakubo; Hiroshi Murata; Atsushi Tanabe; Toshifumi Takeuchi; Tomoe Kusayanagi; Senko Tsukuda; Takeshi Hirakawa; Kazuki Iwabata; Yoshihiro Kanai; Keisuke Ohta; Masahiko Miura; Kengo Sakaguchi; Sachihiro Matsunaga; Hiroeki Sahara; Shinji Kamisuki; Fumio Sugawara
Journal:  Sci Rep       Date:  2015-10-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.